Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
Holding TECH?
Track your performance easily
TECH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$61.16 - $85.57
Previous Close$66.37
Volume1.57M
Average Volume (3M)906.99K
Market Cap
$10.55B
Enterprise Value$10.76B
Total Cash (Recent Filing)$187.54M
Total Debt (Recent Filing)$398.92M
Price to Earnings (P/E)70.7
Beta1.09
Next Earnings
Feb 04, 2025EPS Estimate
$0.39Last Dividend Ex-Date
Nov 08, 2024Dividend Yield0.48%
Share Statistics
EPS (TTM)0.94
Shares Outstanding158,891,800
10 Day Avg. Volume1,239,602
30 Day Avg. Volume906,989
Standard Deviation0.10
R-Squared0.40
Alpha-0.00361
Financial Highlights & Ratios
Price to Book (P/B)4.93
Price to Sales (P/S)9.16
Price to Cash Flow (P/CF)41.60
P/FCF Ratio48.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.18
Enterprise Value/Gross Profit13.98
Enterprise Value/Ebitda36.35
Forecast
1Y Price Target
$84.43Price Target Upside27.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bio-Techne News
PremiumCompany Announcements
Bio-Techne Grants CFO Restricted Stock Units
PremiumCompany Announcements
Bio-Techne Reports First Quarter Fiscal 2025 ResultsBulls Say, Bears Say
Bulls Say
Financial PerformanceBio-Techne delivered FQ4 Revenue / EPS in line with consensus, driven by strong performance in Diagnostics and Genomics.
Market Growth PotentialThe company’s position in multiple growth markets gives confidence TECH can deliver 500-1,000 bps above market growth.
Product InnovationTECH is carving out a winning position in translational spatial biology with COMET, which could become TECH’s highest pull-through instrument yet.
Bears Say
Financial PerformanceDxG operating margins declined to 12.5% from 18.5%, primarily driven by Lunaphore dilution.
Market ExpectationsInvestors expected stable or improving margins due to anticipated end-market recoveries, conflicting with Bio-Techne's forecast of a 100 basis point margin contraction.
Stock PerformanceBio-Techne stock gave back year-to-date gains, down 9.5% compared to XBI's 2.2% decline, following an in-line financial report.
---
Ownership Overview
0.22% Insiders
39.30% Mutual Funds
25.57% Other Institutional Investors
11.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $61.16 and its highest was $85.57 in the past 12 months.
What is Bio-Techne’s market cap?
Currently, no data Available
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Feb 04, 2025 which is in 75 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on Oct 30, 2024. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.382 by $0.038.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.48%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is $0.39.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 158,891,800 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.42 in its last earnings report, beating expectations of $0.382. Following the earnings report the stock price went up 7.472%.
Which hedge fund is a major shareholder of Bio-Techne?
Among the largest hedge funds holding Bio-Techne’s share is Mairs & Power Inc. It holds Bio-Techne’s shares valued at 219M.
---
Bio-Techne Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$84.43 (27.21% Upside)
$84.43 (27.21% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.18%
12-Months-Change
Fundamentals
Return on Equity
7.29%
Trailing 12-Months
Asset Growth
-0.70%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.
---
TECH Earnings Call
Q1 2024
0:00 / 0:00
---
TECH Net revenue Breakdown
71.69% Protein Sciences
28.16% Diagnostics and Genomics
0.36% Other
---
TECH Stock 12 Month Forecast
Average Price Target
$84.43
▲(27.21% Upside)
Technical Analysis
Best Analysts Covering TECH
1 Year
1 Year Success Rate
21/33 ratings generated profit
1 Year Average Return
+13.91%
reiterated a buy rating 21 days ago
Copying Catherine Ramsey Schulte's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +13.91% per trade.
---